Ines Pires da Silva1, Tasnia Ahmed2, Irene L M Reijers3, Alison M Weppler4, Allison Betof Warner5, James Randall Patrinely6, Patricio Serra-Bellver7, Clara Allayous8, Joanna Mangana9, Khang Nguyen10, Lisa Zimmer11, Claudia Trojaniello12, Dan Stout13, Megan Lyle14, Oliver Klein15, Camille L Gerard16, Olivier Michielin16, Andrew Haydon13, Paolo A Ascierto12, Matteo S Carlino1, Celeste Lebbe8, Paul Lorigan17, Douglas B Johnson6, Shahneen Sandhu4, Serigne N Lo2, Christian U Blank3, Alexander M Menzies18, Georgina V Long19. 1. Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia. 2. Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia. 3. Netherlands Cancer Institute, Amsterdam, Netherlands. 4. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. 5. Memorial Sloan Kettering Cancer Center, New York City, NY, USA. 6. Vanderbilt University Medical Center, Nashville, TN, USA. 7. The Christie NHS Foundation Trust, Manchester, UK. 8. AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France. 9. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. 10. Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia. 11. Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 12. Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy. 13. Alfred Hospital, Monash University, Melbourne, VIC, Australia. 14. Cairns Hospital, James Cook University, Cairns, QLD, Australia. 15. Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia. 16. Oncology Department, Lausanne University Hospital, Lausanne, Switzerland. 17. The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. 18. Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia. 19. Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.
Abstract
BACKGROUND: Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. We aimed to determine the efficacy and safety of ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab) compared with ipilimumab monotherapy in patients who are resistant to anti-PD-(L)1 therapy (hereafter referred to as anti-PD-[L]1). METHODS: This multicentre, retrospective, cohort study, was done at 15 melanoma centres in Australia, Europe, and the USA. We included adult patients (aged ≥18 years) with metastatic melanoma (unresectable stage III and IV), who were resistant to anti-PD-(L)1 (innate or acquired resistance) and who then received either ipilimumab monotherapy or ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab), based on availability of therapies or clinical factors determined by the physician, or both. Tumour response was assessed as per standard of care (CT or PET-CT scans every 3 months). The study endpoints were objective response rate, progression-free survival, overall survival, and safety of ipilimumab compared with ipilimumab plus anti-PD-1. FINDINGS: We included 355 patients with metastatic melanoma, resistant to anti-PD-(L)1 (nivolumab, pembrolizumab, or atezolizumab), who had been treated with ipilimumab monotherapy (n=162 [46%]) or ipilimumab plus anti-PD-1 (n=193 [54%]) between Feb 1, 2011, and Feb 6, 2020. At a median follow-up of 22·1 months (IQR 9·5-30·9), the objective response rate was higher with ipilimumab plus anti-PD-1 (60 [31%] of 193 patients) than with ipilimumab monotherapy (21 [13%] of 162 patients; p<0·0001). Overall survival was longer in the ipilimumab plus anti-PD-1 group (median overall survival 20·4 months [95% CI 12·7-34·8]) than with ipilimumab monotherapy (8·8 months [6·1-11·3]; hazard ratio [HR] 0·50, 95% CI 0·38-0·66; p<0·0001). Progression-free survival was also longer with ipilimumab plus anti-PD-1 (median 3·0 months [95% CI 2·6-3·6]) than with ipilimumab (2·6 months [2·4-2·9]; HR 0·69, 95% CI 0·55-0·87; p=0·0019). Similar proportions of patients reported grade 3-5 adverse events in both groups (59 [31%] of 193 patients in the ipilimumab plus anti-PD-1 group vs 54 [33%] of 162 patients in the ipilimumab group). The most common grade 3-5 adverse events were diarrhoea or colitis (23 [12%] of 193 patients in the ipilimumab plus anti-PD-1 group vs 33 [20%] of 162 patients in the ipilimumab group) and increased alanine aminotransferase or aspartate aminotransferase (24 [12%] vs 15 [9%]). One death occurred with ipilimumab 26 days after the last treatment: a colon perforation due to immune-related pancolitis. INTERPRETATION: In patients who are resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 seemed to yield higher efficacy than ipilimumab with a higher objective response rate, longer progression-free, and longer overall survival, with a similar rate of grade 3-5 toxicity. Ipilimumab plus anti-PD-1 should be favoured over ipilimumab alone as a second-line immunotherapy for these patients with advanced melanoma. FUNDING: None.
BACKGROUND: Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. We aimed to determine the efficacy and safety of ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab) compared with ipilimumab monotherapy in patients who are resistant to anti-PD-(L)1 therapy (hereafter referred to as anti-PD-[L]1). METHODS: This multicentre, retrospective, cohort study, was done at 15 melanoma centres in Australia, Europe, and the USA. We included adult patients (aged ≥18 years) with metastatic melanoma (unresectable stage III and IV), who were resistant to anti-PD-(L)1 (innate or acquired resistance) and who then received either ipilimumab monotherapy or ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab), based on availability of therapies or clinical factors determined by the physician, or both. Tumour response was assessed as per standard of care (CT or PET-CT scans every 3 months). The study endpoints were objective response rate, progression-free survival, overall survival, and safety of ipilimumab compared with ipilimumab plus anti-PD-1. FINDINGS: We included 355 patients with metastatic melanoma, resistant to anti-PD-(L)1 (nivolumab, pembrolizumab, or atezolizumab), who had been treated with ipilimumab monotherapy (n=162 [46%]) or ipilimumab plus anti-PD-1 (n=193 [54%]) between Feb 1, 2011, and Feb 6, 2020. At a median follow-up of 22·1 months (IQR 9·5-30·9), the objective response rate was higher with ipilimumab plus anti-PD-1 (60 [31%] of 193 patients) than with ipilimumab monotherapy (21 [13%] of 162 patients; p<0·0001). Overall survival was longer in the ipilimumab plus anti-PD-1 group (median overall survival 20·4 months [95% CI 12·7-34·8]) than with ipilimumab monotherapy (8·8 months [6·1-11·3]; hazard ratio [HR] 0·50, 95% CI 0·38-0·66; p<0·0001). Progression-free survival was also longer with ipilimumab plus anti-PD-1 (median 3·0 months [95% CI 2·6-3·6]) than with ipilimumab (2·6 months [2·4-2·9]; HR 0·69, 95% CI 0·55-0·87; p=0·0019). Similar proportions of patients reported grade 3-5 adverse events in both groups (59 [31%] of 193 patients in the ipilimumab plus anti-PD-1 group vs 54 [33%] of 162 patients in the ipilimumab group). The most common grade 3-5 adverse events were diarrhoea or colitis (23 [12%] of 193 patients in the ipilimumab plus anti-PD-1 group vs 33 [20%] of 162 patients in the ipilimumab group) and increased alanine aminotransferase or aspartate aminotransferase (24 [12%] vs 15 [9%]). One death occurred with ipilimumab 26 days after the last treatment: a colon perforation due to immune-related pancolitis. INTERPRETATION: In patients who are resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 seemed to yield higher efficacy than ipilimumab with a higher objective response rate, longer progression-free, and longer overall survival, with a similar rate of grade 3-5 toxicity. Ipilimumab plus anti-PD-1 should be favoured over ipilimumab alone as a second-line immunotherapy for these patients with advanced melanoma. FUNDING: None.
Authors: Jonathan D Schoenfeld; Anita Giobbie-Hurder; Srinika Ranasinghe; Katrina Z Kao; Ana Lako; Junko Tsuji; Yang Liu; Ryan C Brennick; Ryan D Gentzler; Carrie Lee; Joleen Hubbard; Susanne M Arnold; James L Abbruzzese; Salma K Jabbour; Nataliya V Uboha; Kevin L Stephans; Jennifer M Johnson; Haeseong Park; Liza C Villaruz; Elad Sharon; Howard Streicher; Mansoor M Ahmed; Hayley Lyon; Carrie Cibuskis; Niall Lennon; Aashna Jhaveri; Lin Yang; Jennifer Altreuter; Lauren Gunasti; Jason L Weirather; Raymond H Mak; Mark M Awad; Scott J Rodig; Helen X Chen; Catherine J Wu; Arta M Monjazeb; F Stephen Hodi Journal: Lancet Oncol Date: 2022-01-13 Impact factor: 41.316
Authors: Ines Pires da Silva; Danny Zakria; Tasnia Ahmed; Claudia Trojanello; Florentia Dimitriou; Clara Allayous; Camille Gerard; Lisa Zimmer; Serigne Lo; Olivier Michielin; Celeste Lebbe; Johanna Mangana; Paolo Antonio Ascierto; Douglas B Johnson; Matteo Carlino; Alexander Menzies; Georgina Long Journal: J Immunother Cancer Date: 2022-07 Impact factor: 12.469
Authors: David M O'Malley; Maryna Neffa; Bradley J Monk; Tamar Melkadze; Marilyn Huang; Anna Kryzhanivska; Iurie Bulat; Tarek M Meniawy; Andrea Bagameri; Edward W Wang; Bernard Doger de Speville Uribe; Roberto Hegg; Waldo Ortuzar Feliu; Marek Ancukiewicz; Iwona Lugowska Journal: J Clin Oncol Date: 2021-12-21 Impact factor: 50.717
Authors: Paolo A Ascierto; Allison Betof Warner; Christian Blank; Corrado Caracò; Sandra Demaria; Jeffrey E Gershenwald; Nikhil I Khushalani; Georgina V Long; Jason J Luke; Janice M Mehnert; Caroline Robert; Piotr Rutkowski; Hussein A Tawbi; Iman Osman; Igor Puzanov Journal: J Transl Med Date: 2022-05-10 Impact factor: 8.440
Authors: Omar Fahmy; Nabil A Alhakamy; Mohd G Khairul-Asri; Osama A A Ahmed; Usama A Fahmy; Claudia G Fresta; Giuseppe Caruso Journal: J Pers Med Date: 2021-12-23